March 27, 2020
A quick rundown of impressive activities in university labs and startups
In ways imaginative and pragmatic, Georgia’s university scientists and startup companies have gotten into the fight against COVID-19.
Here are some examples of how GRA-backed researchers and entrepreneurs in our state are applying expertise and ingenuity against the coronavirus.An experimental drug developed at Emory University to treat the COVID-19 disease is advancing toward human testing. The treatment is being licensed by Ridgeback Biotherapeutics through DRIVE, LLC, an Emory nonprofit working to bring the drug to market.
January 29, 2020
Our notebook from the 2020 Academy of GRA Eminent Scholars
Synthetic chemistry could yield compounds that defeat drug-resistant bacteria. Electrical power generation and distribution is changing at a staggering pace. Genetically identical twins experience high blood pressure differently.
Emerging drugs for cystic fibrosis will increase life expectancy by decades.
October 2, 2019
Funding validates GRA's Eminent Scholar model
This week’s news that the National Institutes of Health (NIH) has awarded two Georgia universities major grants to advance work toward a universal flu vaccine is more than a testament to their sophisticated research programs. It also reflects how the Georgia Research Alliance’s efforts to recruit world-class scientists to Georgia can pay off in a big way.
On September 30, the University of Georgia and Emory University each announced it would play leadership roles in a nationwide effort to accelerate pursuit of the vaccine, considered the “Holy Grail” of influenza prevention. Combined, the NIH grants to the two institutions – made through its Collaborative Influenza Vaccine Innovation Centers (CIVICs) – could exceed $200 million in the years to come.